Guillain Barré Syndrome in a multiple myeloma patient after the first course of bortezomib therapy: A case report

Dai,Xingbin; Sun,Xuemei; Ni,Haiwen; Zhu,Xuejun

doi:10.3892/ol.2015.3634

November-2015 Volume 10 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

November-2015 Volume 10 Issue 5

Full Size Image

Case Report

Guillain Barré Syndrome in a multiple myeloma patient after the first course of bortezomib therapy: A case report

Authors:
- Xingbin Dai
- Xuemei Sun
- Haiwen Ni
- Xuejun Zhu
View Affiliations / Copyright

Affiliations: Department of Hematology, Jiangsu Province Hospital Affiliated to Nanjing University of Traditional Chinese Medicine, Nanjing, Jiangsu, P.R. China
Pages: 3064-3066
|
Published online on: August 25, 2015

https://doi.org/10.3892/ol.2015.3634
Expand metrics +

Abstract

Bortezomib is approved for treating relapsed multiple myeloma (MM) and mantle cell lymphoma, and clinical evidence has shown complete clinical responses in MM patients. Peripheral neuropathy is one of the most common adverse effects of bortezomib. However, rare evidence has shown that bortezomib is associated with Guillain‑Barré syndrome (GBS). In the present study, a case of GBS is reported in an MM patient finishing the first course of bortezomib therapy. Based on a bone marrow cell examination revealing 34% plasma cell infiltration and according to the International Staging System, the patient was diagnosed with stage III MM (λ type). Thus, a chemotherapy protocol was performed, which consisted of bortezomib and dexamethasone. However, 5 days after the first cycle, paresthesias of the upper and lower limbs developed. Standard nerve conduction studies revealed marked reduction of the motor conduction velocity of the median nerve bilaterally and of the right ulnar nerve, while sensory conduction was significantly slowed in the majority of the nerves of the upper and lower limbs. However, there was no evidence of demyelination. With this clinical evidence, a diagnosis of GBS was considered. The patient was subsequently treated with high‑dose intravenous immunoglobulins (IVIGs; 400 mg/kg/day for 5 days). Following IVIG treatment, the symptoms were largely relieved. This study suggested that GBS may occur when administering bortezomib, and that high‑dose IVIGs could treat the symptoms of GBS.

View Figures

View References

1	Kyle RA and Rajkumar SV: Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 23:3–9. 2009. View Article : Google Scholar : PubMed/NCBI
2	Morgan GJ and Davies FE: Evolving treatment strategies for myeloma. Br J Cancer. 92:217–221. 2005.PubMed/NCBI
3	Winer JB: Treatment of Guillain-Barré syndrome. QJM. 95:717–721. 2002. View Article : Google Scholar : PubMed/NCBI
4	Velcade® (bortezomib) [package insert]. Millennium Pharmaceuticals, Inc.; Cambridge, MA, USA: 2008
5	Greipp PR, Miquel J San, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, et al: International staging system for multiple myeloma. J Clin Oncol. 23:3412–3420. 2005. View Article : Google Scholar : PubMed/NCBI
6	Brooke MH, Fenichel GM, Griggs RC, Mendell JR, Moxley R, Miller JP and Province MA: Clinical investigation in Duchenne dystrophy: 2. Determination of the “power” of therapeutic trials based on the natural history. Muscle Nerve. 6:91–103. 1983. View Article : Google Scholar : PubMed/NCBI
7	Yuki N and Hartung HP: Guillain-Barré syndrome. N Engl J Med. 366:2294–2304. 2012. View Article : Google Scholar : PubMed/NCBI
8	Rosen BA: Guillain-Barré Syndrome. Pediatr Rev. 33:164–170. 2012. View Article : Google Scholar : PubMed/NCBI
9	Richardson PG, Laubach JP, Schlossman RL, Mitsiades C and Anderson K: Complications of multiple myeloma therapy, part 1: Risk reduction and management of peripheral neuropathy and asthenia. J Natl Compr Canc Netw. 8(Suppl 1): S4–S12. 2010.PubMed/NCBI
10	Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, et al: Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 24:3113–3120. 2006. View Article : Google Scholar : PubMed/NCBI
11	Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al: Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 352:2487–2498. 2005. View Article : Google Scholar : PubMed/NCBI
12	Dimopoulos MA, Mateos MV, Richardson PG, Schlag R, Khuageva NK, Shpilberg O, et al: Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: Subanalysis of the phase 3 VISTA study. Eur J Haematol. 86:23–31. 2011. View Article : Google Scholar : PubMed/NCBI
13	Rampen AJ, Jongen JL, van Heuvel I, Scheltens-de Boer M, Sonneveld P and van den Bent MJ: Bortezomib-induced polyneuropathy. Neth J Med. 71:128–133. 2013.PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Guillain Barré Syndrome in a multiple myeloma patient after the first course of bortezomib therapy: A case report

This article is mentioned in:

Abstract

Related Articles